Cargando…

Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum

Tissue-engineered skin substitutes (TESs) are used as a treatment for severe burn injuries. Their production requires culturing both keratinocytes and fibroblasts. The methods to grow these cells have evolved over the years, but bovine serum is still commonly used in the culture medium. Because of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Doucet, Emilie J., Cortez Ghio, Sergio, Barbier, Martin A., Savard, Étienne, Magne, Brice, Safoine, Meryem, Larouche, Danielle, Fradette, Julie, Germain, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454817/
https://www.ncbi.nlm.nih.gov/pubmed/37628718
http://dx.doi.org/10.3390/ijms241612537
_version_ 1785096291931389952
author Doucet, Emilie J.
Cortez Ghio, Sergio
Barbier, Martin A.
Savard, Étienne
Magne, Brice
Safoine, Meryem
Larouche, Danielle
Fradette, Julie
Germain, Lucie
author_facet Doucet, Emilie J.
Cortez Ghio, Sergio
Barbier, Martin A.
Savard, Étienne
Magne, Brice
Safoine, Meryem
Larouche, Danielle
Fradette, Julie
Germain, Lucie
author_sort Doucet, Emilie J.
collection PubMed
description Tissue-engineered skin substitutes (TESs) are used as a treatment for severe burn injuries. Their production requires culturing both keratinocytes and fibroblasts. The methods to grow these cells have evolved over the years, but bovine serum is still commonly used in the culture medium. Because of the drawbacks associated with the use of serum, it would be advantageous to use serum-free media for the production of TESs. In a previous study, we developed a serum-free medium (Surge SFM) for the culture of keratinocytes. Herein, we tested the use of this medium, together with a commercially available serum-free medium for fibroblasts (Prime XV), to produce serum-free TESs. Our results show that serum-free TESs are macroscopically and histologically similar to skin substitutes produced with conventional serum-containing media. TESs produced with either culture media expressed keratin 14, Ki-67, transglutaminase 1, filaggrin, type I and IV collagen, and fibronectin comparably. Mechanical properties, such as contraction and tensile strength, were comparable between TESs cultured with and without serum. Serum-free TESs were also successfully grafted onto athymic mice for a six-month period. In conclusion, Surge SFM and Prime XV serum-free media could be used to produce high quality clinical-grade skin substitutes.
format Online
Article
Text
id pubmed-10454817
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104548172023-08-26 Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum Doucet, Emilie J. Cortez Ghio, Sergio Barbier, Martin A. Savard, Étienne Magne, Brice Safoine, Meryem Larouche, Danielle Fradette, Julie Germain, Lucie Int J Mol Sci Article Tissue-engineered skin substitutes (TESs) are used as a treatment for severe burn injuries. Their production requires culturing both keratinocytes and fibroblasts. The methods to grow these cells have evolved over the years, but bovine serum is still commonly used in the culture medium. Because of the drawbacks associated with the use of serum, it would be advantageous to use serum-free media for the production of TESs. In a previous study, we developed a serum-free medium (Surge SFM) for the culture of keratinocytes. Herein, we tested the use of this medium, together with a commercially available serum-free medium for fibroblasts (Prime XV), to produce serum-free TESs. Our results show that serum-free TESs are macroscopically and histologically similar to skin substitutes produced with conventional serum-containing media. TESs produced with either culture media expressed keratin 14, Ki-67, transglutaminase 1, filaggrin, type I and IV collagen, and fibronectin comparably. Mechanical properties, such as contraction and tensile strength, were comparable between TESs cultured with and without serum. Serum-free TESs were also successfully grafted onto athymic mice for a six-month period. In conclusion, Surge SFM and Prime XV serum-free media could be used to produce high quality clinical-grade skin substitutes. MDPI 2023-08-08 /pmc/articles/PMC10454817/ /pubmed/37628718 http://dx.doi.org/10.3390/ijms241612537 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Doucet, Emilie J.
Cortez Ghio, Sergio
Barbier, Martin A.
Savard, Étienne
Magne, Brice
Safoine, Meryem
Larouche, Danielle
Fradette, Julie
Germain, Lucie
Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
title Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
title_full Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
title_fullStr Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
title_full_unstemmed Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
title_short Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
title_sort production of tissue-engineered skin substitutes for clinical applications: elimination of serum
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454817/
https://www.ncbi.nlm.nih.gov/pubmed/37628718
http://dx.doi.org/10.3390/ijms241612537
work_keys_str_mv AT doucetemiliej productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT cortezghiosergio productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT barbiermartina productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT savardetienne productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT magnebrice productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT safoinemeryem productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT larouchedanielle productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT fradettejulie productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum
AT germainlucie productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum